GlassScriptPhysician profile
Kelli V Burroughs
NPI 1104062678
$2,086.38
in general payments reported to CMS, 2019-2025
28 companies · $64.74 in 2025
The $64.74 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $465 · 2021: $151 · 2022: $385 · 2023: $417 · 2024: $254 · 2025: $64.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.03 | 2019-2024 | Lo Loestrin Fe |
| Lupin INC. | $266.01 | 2019-2021 | |
| Pfizer INC. | $213.40 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $166.74 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $152.14 | 2023 | Myfembree |
| Exeltis, USA INC. | $137.90 | 2023-2024 | Slynd, Solosec |
| Astellas Pharma US INC | $123.02 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $97.70 | 2020-2021 | |
| Therapeuticsmd, INC. | $65.32 | 2019-2020 | |
| Millicent US INC | $56.32 | 2024 | Intrarosa, Femring |
| Myovant Sciences INC. | $55.28 | 2022 | |
| Amgen INC. | $46.84 | 2019-2020 | |
| Allergan, INC. | $44.42 | 2019 | |
| Hologic Sales and Service, LLC | $42.98 | 2021-2025 | Fluent Fluid Management System, Novasure |
| Organon LLC | $41.37 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $40.63 | 2023 | Twirla |
| Amag Pharmaceuticals, INC. | $36.10 | 2019 | |
| Radius Health, INC. | $33.52 | 2019 | |
| Avion Pharmaceuticals | $28.43 | 2020-2023 | Balcoltra |
| Medtronic, INC. | $23.41 | 2022 | |
| Evofem Biosciences, INC. | $18.64 | 2020 | |
| Ethicon US, LLC | $18.45 | 2025 | Enseal |
| Covidien LP | $17.03 | 2020 | |
| Currax Pharmaceuticals LLC | $16.52 | 2023 | Contrave |
| Vertical Pharmaceuticals, LLC | $16.13 | 2019 | |
| Ascend Therapeutics US, LLC | $14.77 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2019 | |
| Coopersurgical, INC. | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.